Storia in 2 fonti

Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer

Karyopharm shares crater 65% after Xpovio fails Phase 3 endometrial cancer trial; company pivots to myelofibrosis label bid.

Raccontata da

endpoints.news

fiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo12 h fa

Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer

Karyopharm shares crater 65% after Xpovio fails Phase 3 endometrial cancer trial; company pivots to myelofibrosis label bid.

originale

fiercepharma.com9 h fa

Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis

Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in Marc | Reporting a new…

Leggi questa versione → originale

Timeline cronologica

venerdì 31 luglio 2026·endpoints.news
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
Karyopharm shares crater 65% after Xpovio fails Phase 3 endometrial cancer trial; company pivots to myelofibrosis label bid.
venerdì 31 luglio 2026·fiercepharma.com
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that…